Key clinical point: A tight control strategy led to long-term remission in 31.5% of patients with rheumatoid arthritis (RA) in real-world practice, with certain clinical and demographic characteristics being independent predictors.
Major finding: Long-term remission was achieved by 31.5% of patients and was independently predicted by disease characteristics, such as absence of flare during disease course (odds ratio [OR] 15.12; P = .001), sustained remission at ≤6 months after starting therapy (OR 3.24; P = .001), and baseline Disease Activity Score in 28 joints of ≤5.1 (OR 2.36; P = .037). Other factors included demographic factors, such as age >60 years at disease onset (OR 2.71; P = .029), and being anticitrullinated protein antibody negative (OR 2.63; P = .008).
Study details: This longitudinal study included 499 patients with RA who were treated with a tight control strategy, including step-up combination therapy with conventional synthetic and biologic disease-modifying antirheumatic drugs.
Disclosures: This study did not report the funding source or any conflicts of interest.
Source: Khabbazi A et al. Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: A longitudinal study. Clin Rheumatol . 2023 (Feb 17). Doi: 10.1007/s10067-023-06548-1